NSNoah Scheinfeld

Noah Scheinfeld

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noah Scheinfeld has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pairing and comparing nine diseases with Degos Disease (Malignant Atrophic Papulosis): An attempt to illustrate our understanding and direct future inquiry

    by Noah Scheinfeld

    Degos disease is a poorly defined condition that encompasses cutaneous and systemic findings that overlap with a large number of other rheumatologic and coagulation disorders. Comparisons are made herein with 9 conditions that share findings and presentations.


  • Pruritic urticarial papules and plaques of pregnancy wholly abated with one week twice daily application of fluticasone propionate lotion: A case report and review of the literature

    by Noah Scheinfeld

    Pruritic urticarial papules and plaques of pregnancy (PUPPP) is among the most common dermatoses of pregnancy. Most reports of the effective treatment of PUPPP involve high potency topical corticosteroids or oral steroids. Many authorities have noted cases of PUPPP whose resolution followed parturition. A few have noted that PUPPP can arise and resolve the third trimester. A 36-year-old prima gravida at 38 weeks of gestation presented with a 2-week history of a pruritic papular abdominal eruption. She used fluticasone propionate 0.05 percent lotion twice a day. One week after starting this medication, the pruritus had resolved and the erythema/urticaria had abated; the pigmentary alteration had improved, but still remained. The PUPPP did not return after parturition. PUPPP can abate entirely during pregnancy. Fluticasone propionate 0.05 percent lotion, a class 5 (low-medium potency) corticosteroid, has a benign side effect profile and should be considered for the treatment of PUPPP during pregnancy.


  • The use and safety of doxycycline hyclate and other second-generation tetracyclines

    by Barry Sloan, Noah Scheinfeld

    Tetracyclines have long been used to treat a wide variety of medical conditions, especially in the field of dermatology. Unfortunately, safety concerns, especially gastrointestinal (GI), have always been present. Other safety concerns have included tooth development in children, candidiasis, vestibular concerns, photosensitivity/phototoxicity, and more unusual adverse effects such as uncontrolled hypertension. This article first discusses the pharmacological development of the tetracyclines from the first to the second generation versions with an emphasis on the safety concerns, especially with regards to doxycycline hyclate (DH). Second, the adverse effects of the tetracyclines are discussed. Third, the favorable side effect profile of DH delayed release capsules (Doryx) is compared with DH powder contained in tablets (Vibramycin). Fourth, the increased use with a continued favorable safety profile is also discussed concerning the subantimicrobial dosing of DH for acne. Fifth, the safety of periodontic uses of DH is discussed. Last, the favorable safety profiles of the 2006 approved uses of an anti-inflammatory dose of 40 mg doxycycline for rosacea and an extended-release minocycline tablet for acne are also discussed.


  • Myfortic® (mycophenolate sodium) delayed-release tablets

    by Ansa Qureshi, Noah Scheinfeld

    Author(s): Qureshi, Ansa; Scheinfeld, Noah


  • Ketoconazole: A review of a workhorse antifungal molecule with a focus on new foam and gel formulations

    by N. Scheinfeld

    Topical ketoconazole, an imidazole, has been a mainstay of treatment for fungal infections and seborrheic dermatitis. Ketoconazole interferes with the fungal synthesis of ergosterol, a constituent of cell membranes, and has other antifungal effects. Shampoo, cream and oral formulations of ketoconazole have been available for many years. Recently, new foam and gel formulations of ketoconazole have been brought to market for the treatment of seborrheic dermatitis, which are effective against superficial fungal and yeast infections. The foam and gel formulations are likely to lead to a renascence of use of topical ketocona- zole for the treatment of skin disease, as patient preference and compliance might be augmented with such vehicles.


  • Menorrhagia and severe menstrual pain related to the use of adalimumab in a psoriatic

    by Noah Scheinfeld

    The case is reported of a 32-year-old morbidly obese white woman who used adalimumab 40 mg every other week for 4 months for psoriatic arthritis, psoriasis vulgaris and inverse psoriasis with total clearance of her psoriasis who developed menorrhagia (at least twice the number of pads used daily for 4-6 days as opposed to 3-5 days previously) and severe menstrual pain. Treatment with Aviane (ethinyl estradiol and levonorgestrel) abated some of these menstrual symptoms. The symptoms resolved altogether when the adalimumab was discontinued. Menstrual disorders are listed as possible side effects from the use of infliximab and adalimumab in their respective package inserts and also for adalimumab and etanercept in the United Kingdom's Medicines and Healthcare products Regulatory Agency's drug side-effect database, but few case reports of menstrual side effects exist from including tumor necrosis alpha (TNFalpha) blockers. Physicians should be aware of the menstrual side effects of adalimumab and the role of oral contraceptive pills in treating such menstrual side effects.


  • A review and report of blistering distal dactylitis due to Staphylococcus aureus in two HIV-positive men

    by Noah Scheinfeld

    Blistering distal dactylitis (BDD) is attributed to infection with group A beta-hemolytic Streptococcus or Staphylococcus aureus (SA). Although initially described in children, BDD subsequently has also been reported in adults. It occurs in the immunocompetent and immunocompromised individuals. This report notes two HIV-positive men with BDD, one with bullae and the other with erosions caused by SA, effectively treated with amoxicillin trihydrate/clavulanate potassium. This report highlights the reasoning behind adjusting empiric therapy to account for SA, that BDD can present with erosions, and that the course and presentation of BDD in HIV-positive patients mirrors that of non HIV-positive patients.


  • Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone

    by Noah Scheinfeld

    Mycophenolate mofetil (MMF) is an immunosuppressive drug used in renal transplantation, lupus nephritis and pemphigus vulgaris patients. An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia. Specifically, after initiation of 500 mg MMF twice a day given in conjunction with the long‐standing use of prednisone, which had been tapered to a dose of 10 mg daily, the patient's red blood cell count dropped by 17% over 7 weeks. To put this into perspective, total aplasia of red blood cells for 40 days would result in a drop of 30–33% in the red blood cell count. In the transplantation literature, MMF has been noted to lower red blood cell counts. One previous study of four transplant patients whose immediate post‐transplantation immunosuppression utilized corticosteroids, cyclosporine, MMF, and anti‐T‐lymphocyte globulin noted anemia in 13% of them. The dermatology literature heretofore has not noted that anemia is a side effect of patients taking MMF to treat pemphigus. This report suggests that anemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. It would therefore seem prudent to monitor red and white blood cell counts in patients taking MMF. A review of the literature also reveals that MMF is a safe medication that appears to have a more favorable side effect profile than azathioprine, although it is more expensive than azathioprine.


  • Dalbavancin: A review

    by N. Scheinfeld

    Dalbavancin is a second-generation lipoglycopeptide bactericidal agent. Due to its once-weekly intravenous (i.v.) dosing and greater tissue penetration, dalbavancin may offer advantages in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) as compared to vancomycin, the gold standard in the treatment of MRSA. Dalbavancin binds to the terminal D-alanyl-D-alanine moiety of peptidoglycan precursors in bacterial cell walls. Such binding blocks enzymes involved in the final stages of peptidoglycan synthesis and cell wall formation. Dalbavancin exhibits an elimination half-life of approximately 200 hours, allowing it to be dosed weekly. The best-studied dosing schedule for dalbavancin involves the i.v. administration of 1 g of dalbavancin followed by 500 mg one week later. Phase III clinical trials comprising more than 1,500 patients evaluated once-weekly dalbavancin in Gram-positive skin and soft tissue infections (SSTIs). When compared to linezolid, cefazolin or vancomycin, dalbavancin met the primary endpoint of noninferiority at two weeks following therapy. The side-effect profile of dalbavancin is mild, with headache and pyrexia being the most common adverse effects. Dalbavancin is eliminated renally and hepatically, and does not need dose adjustments in patients with renal insufficiency. Once-weekly dosing with dalbavancin gives it another advantage when compared with vancomycin, and may alleviate the need for the continued presence of indwelling catheters in some patients with SSTIs and other infections requiring prolonged doses of antibiotics. While some in vitro evidence supports dalbavancin's effectiveness against vancomycin-resistant S. aureus, the preponderance of in vivo evidence does not demonstrate its effectiveness against vancomycin-resistant S. aureus.